Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan + Intrathecal Pemetrexed for LM from HER2- Breast Cancer
NCT06462092Phase 2Recruiting
- Sponsor
- Guangzhou Medical University
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, pemetrexed in leptomeningeal metastases (LM), breast cancer, sponsored by Guangzhou Medical University. Started Jan 2026; status: recruiting.
02
Drugs
sacituzumab govitecanpemetrexed
03
Conditions
leptomeningeal metastases (LM)breast cancer
Beyond the preview
Go deeper on NCT06462092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462092.